Cardiotoxicity of beta-mimetic catecholamines during ontogenetic development - possible risks of antenatal therapy

0492488 - FGÚ 2019 RIV CA eng J - Článek v odborném periodiku
Ošťádal, Bohuslav - Pařízek, A. - Ošťádalová, Ivana - Kolář, František
Cardiotoxicity of beta-mimetic catecholamines during ontogenetic development - possible risks of antenatal therapy.
Canadian Journal of Physiology and Pharmacology. Roč. 96, č. 7 (2018), s. 639-646. ISSN 0008-4212. E-ISSN 1205-7541
Grant CEP: GA ČR(CZ) GA16-06825S; GA ČR(CZ) GA16-02972S
Institucionální podpora: RVO:67985823
Klíčová slova: beta-mimetic catecholamines * cardiotoxicity * immature heart * preterm labor * tocolysis
Obor OECD: Physiology (including cytology)
Impakt faktor: 2.041, rok: 2018

Catecholamines are involved in the regulation of a wide variety of vital functions. The beta-adrenergic receptor (beta-AR) adenylyl cyclase system has been identified early in embryogenesis before the heart has received adrenergic innervation. The structure of beta-receptors in the immature myocardium is similar to that in adults, there are, however, significant quantitative developmental changes in the inotropic and chronotropic responsiveness. Information on the toxic effect of the beta-AR agonists in the immature heart is surprisingly scarce, even though these agents are used in clinical practice both during pregnancy and in early postnatal development. Large doses of beta-AR agonists induce malformations of the cardiovascular system, the type of change depends upon the time at which the beta-AR agonist was administered during embryogenesis. During postnatal ontogeny, the cardiotoxicity of beta-AR agonists increased from birth to adulthood. It seems likely that despite interspecies differences, developmental changes in the cardiac sensitivity to beta-AR agonists may exist in all mammals, depending on the degree of maturation of the system involved in beta-adrenergic signaling. All the existing data draw attention to the possible harmful consequences of the clinical use of beta-AR agonists during early phases of cardiac development. Late effects of the early disturbances of the cardiac muscle cannot be excluded.
Trvalý link: http://hdl.handle.net/11104/0286001